April 28th 2025
New research suggests classical biomarkers cannot discriminate between refractory and non-refractory rheumatoid arthritis.
Atopic Dermatitis Severity, Age at Diagnosis May Increase Risk of Ophthalmic Diseases
November 25th 2021Moderate-to-severe disease, childhood onset, and systemic treatments were all associated with a greater risk of conjunctivitis in patients with atopic dermatitis, whereas use of soft and hard contact lenses were linked with risk of keratitis.
Read More
Risk of Severe COVID-19 Heightened in Patients With Obstructive Sleep Apnea
November 24th 2021In Icelandic patients, obstructive sleep apnea were associated with a 2-fold increased risk of severe COVID-19 that required hospitalization or led to death after accounting for obesity and other comorbidities.
Read More
George Van Antwerp: Specialty Drugs Rely on Personalization for Optimal Outcomes
November 24th 2021The high cost of specialty drugs makes it important to use companion diagnostics and other tests to make sure the drug is going to the right patient, said George Van Antwerp, MBA, managing director, Deloitte Consulting.
Watch
Machine Learning Approach Finds Several Severity-Associated Factors in Atopic Dermatitis
November 23rd 2021Findings of a machine learning-based deep phenotyping approach found a myriad of factors associated with severe disease in atopic dermatitis, including age between 12 and 21 years or older than 52 years, lack of physical activity, and incidence of alopecia areata.
Read More
Achieving Equitable Breast Cancer Care: Clinical Trials, Mental Health, and Digital Therapeutics
November 23rd 2021Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.
Read More
With No Replacement for OCM on Horizon, Oncology Practices Ask: What Now?
November 22nd 2021The announcement of a "strategic refresh" for payment models under the Center for Medicare and Medicaid Innovation offered no details on what practices should expect when the Oncology Care Model (OCM) expires in 2022.
Read More
Contributor: Congress Must Do More to Cover Nonopioid Alternatives
November 21st 2021Preventing addiction is key to ending the opioid epidemic—2020 alone saw more than 93,000 overdose deaths—as are expanding access to treatment, promoting recovery, and building a multifaceted strategy that incorporates nonopioid alternative and their coverage by providers. Although appropriate in certain situations, opioids are not a one-size-fits-all approach.
Read More
Dr Daniel Greer on Emergence of CBT as First-line Treatment for Chronic Insomnia
November 20th 2021Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, discusses the use of cognitive behavioral therapy (CBT) as a first-line treatment for chronic insomnia and barriers limiting its use.
Watch
Dr Robert Hopkin on Emerging Therapeutic, Technological Advancements in Fabry Disease
November 19th 2021Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, discusses current and emerging therapeutic and technological advancements in the management of Fabry disease.
Watch
Bariatric Surgery Reduced Risk of Major Adverse Liver, CV Outcomes in Patients With NASH
November 18th 2021Patients with nonalcoholic steatohepatitis (NASH) and obesity had a reduced risk of major adverse liver outcomes and major adverse cardiovascular (CV) events after they underwent bariatric surgery compared with patients who did not have surgery.
Read More
Sacubitril/Valsartan Treatment for HFpEF Shown to Reduce NT-proBNP Levels
November 18th 2021Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure with preserved ejection fraction (HFpEF).
Read More
Dr Jonathan Silverberg on Potential Benefits, Challenges of JAK Inhibitor Use in Atopic Dermatitis
November 17th 2021Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, explains efficacy and safety implications of JAK inhibitor use for atopic dermatitis.
Watch
Guselkumab Linked With Long-term Improvement of Joint Manifestations, Disease Activity in PsA
November 17th 2021Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.
Read More
HRQOL Decreased During and Immediately After CAR T-Cell Therapy for DLBCL
November 16th 2021Prior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy.
Read More
Teprotumumab Benefits Patients With Mild Inflammation and Real-world Adherence Remains High
November 15th 2021Posters presented at the American Academy of Ophthalmology 2021 annual meeting showed that even patients with mild inflammation with their thyroid eye disease benefitted from teprotumumab and that real-world adherence was consistent with the pivotal clinical trials.
Read More
Teprotumumab, Enhanced Monofocal IOLs Among Hot Topics at AAO 2021
November 15th 2021Among many presentations during a hot topics session at the American Academy of Ophthalmology 2021 annual meeting, speakers discussed the first FDA approved therapy for thyroid eye disease and the latest in enhanced monofocal intraocular lenses (IOLs).
Read More
Ophthalmology at Crossroads for Information Technology, AI
November 14th 2021The field of ophthalmology had already been moving toward telehealth and artificial intelligence (AI) before the COVID-19 pandemic, but these changes are being accelerated now, making it crucial for ophthalmologists to learn to adapt.
Read More
Pathologists Discuss Actionable Mutations and Testing in Metastatic Breast Cancer
November 14th 2021Genetic profiling in recurrent and advanced breast cancer can yield actionable, smoking-gun biomarkers, Stanford Cancer Institute pathologists explained at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors.
Read More
Posters at AAO 2021 Analyze ED Utilization for Nonemergency Ophthalmic Conditions
November 13th 2021Emergency department utilization for nonemergent ophthalmic conditions is on the rise in the United States, but presentation types vary significantly based on patient demographics, according to 2 posters presented at the American Academy of Ophthalmology (AAO) 2021 meeting.
Read More
Dr William Katowitz Discusses Pediatric Ophthalmic Surgical Decisions
November 13th 2021Surgical decisions with children who have ophthalmic conditions need buy in from parents, but also the children as they get older, said William Katowitz, MD, attending surgeon in the Division of Ophthalmology at Children's Hospital of Philadelphia.
Watch
Access to Optimal Care Has Stymied Visual Acuity Gains in AMD With Anti-VEGF Treatment
November 13th 2021The real-world visual acuity gains in age-related macular degeneration (AMD) after treatment have been inferior to those seen in clinical trials, explained a speaker during the American Academy of Ophthalmology 2021 meeting.
Read More
Survey of Australian Oncologists Finds Room for Increasing Their Confidence With CGP
November 12th 2021A recent survey of oncologists in Australia showed that while most are integrating comprehensive genomic profiling (CGP) into their practice, they lack a high level of confidence to communicate findings and to adjust patient treatment accordingly.
Read More
Recommendations, Insights on Use of Comprehensive Genomic Profiling in Oncology
November 12th 2021A discussion at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors addressed the advantages and considerations for broad and targeted genomic profiling in oncology.
Read More
Prior Biologic Use, Body Weight May Impact Guselkumab Efficacy in Psoriasis
November 12th 2021Real-world patients with moderate-to-severe psoriasis were shown to exhibit impaired efficacy with guselkumab treatment if they had history of prior biologic use, particularly anti-interleukin (IL)-17 exposure, with heavier patients linked with delayed onset of therapeutic response.
Read More